Advanced in Mesothelioma

Dr. Pasi A. Janne

Oncology
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
Accepting New Patients
Offers Telehealth
Advanced in Mesothelioma
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Pasi Janne is an Oncologist in Boston, Massachusetts. Dr. Janne is rated as an Advanced provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy. Dr. Janne is currently accepting new patients.

His clinical research consists of co-authoring 392 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles in the study of Mesothelioma.

Specialties
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

DANA-FARBER CANCER INSTITUTE, INC.
450 Brookline Ave, Boston, MA 02215
Other Locations
DANA-FARBER CANCER INSTITUTE, INC.
20 Prospect St, Suite 2, Milford, MA 01757

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase I Trial of Osimertinib (AZD9291) and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
A Phase I Trial of Osimertinib (AZD9291) and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Necitumumab, Osimertinib
Study Phase: Phase 1
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2025
Intervention Type: Drug
Study Drugs: Osimertinib, Selumetinib
Study Phase: Phase 2
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Mutation
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Mutation
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Drug
Study Drug: DZD9008
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Osimertinib in Combination With Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
A Phase 1/2 Study of Osimertinib in Combination With Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2025
Intervention Type: Drug
Study Drugs: Gefitinib, Osimertinib
Study Phase: Phase 1/Phase 2
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3
MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics & Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients w/ Advanced Solid Malignancies
MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics & Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients w/ Advanced Solid Malignancies
Enrollment Status: Terminated
Publish Date: April 17, 2025
Intervention Type: Drug
Study Drug: BDTX-189
Study Phase: Phase 1
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: August 01, 2023
Intervention Type: Biological
Study Drug: Enapotamab vedotin 
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants With Relapsed/Refractory Solid Tumors
A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants With Relapsed/Refractory Solid Tumors
Enrollment Status: Unknown
Publish Date: September 01, 2022
Intervention Type: Drug
Study Drug: RMC-4630
Study Phase: Phase 1
ALCMI-012 A Prospective Biospecimen Collection Study From Patients With EGFR Mutant Tumors
ALCMI-012 A Prospective Biospecimen Collection Study From Patients With EGFR Mutant Tumors
Enrollment Status: Withdrawn
Publish Date: January 09, 2020
A Phase II Randomized Study of OSI-774 (Erlotinib) (NSC #718781) With or Without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers
A Phase II Randomized Study of OSI-774 (Erlotinib) (NSC #718781) With or Without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers
Enrollment Status: Completed
Publish Date: August 07, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 in Combination With Docetaxel, Compared With Docetaxel Alone, in 2nd Line Patients With KRAS Mutation Positive Locally Advanced Metastatic NSCLC
Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 in Combination With Docetaxel, Compared With Docetaxel Alone, in 2nd Line Patients With KRAS Mutation Positive Locally Advanced Metastatic NSCLC
Enrollment Status: Completed
Publish Date: June 20, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

392 Total Publications

Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry.
Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry.
Journal: JCO precision oncology
Published: December 05, 2025
Similar Doctors
Elite in Mesothelioma
Dr. David J. Kwiatkowski
Oncology
Elite in Mesothelioma
Dr. David J. Kwiatkowski
Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Kwiatkowski is an Oncologist in Boston, Massachusetts. Dr. Kwiatkowski is rated as an Elite provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Lung Adenocarcinoma, Lung Cancer, Mesothelioma, and Non-Small Cell Lung Cancer (NSCLC).

Ibiayi Dagogo-Jack
Elite in Mesothelioma
Dr. Ibiayi Dagogo-Jack
Hematology Oncology | Oncology | Hematology
Elite in Mesothelioma
Dr. Ibiayi Dagogo-Jack
Hematology Oncology | Oncology | Hematology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ibiayi Dagogo-Jack is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Dagogo-Jack is rated as an Elite provider by MediFind in the treatment of Mesothelioma. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Lung Adenocarcinoma, and Tissue Biopsy. Dr. Dagogo-Jack is currently accepting new patients.

Distinguished in Mesothelioma
Dr. David M. Jackman
Oncology
Distinguished in Mesothelioma
Dr. David M. Jackman
Oncology

Dana-Farber Cancer Institute, Inc.

300 Boylston St, Suite 301, 
Chestnut Hill, MA 
 (3.9 miles away)
617-632-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Jackman is an Oncologist in Chestnut Hill, Massachusetts. Dr. Jackman is rated as an Elite provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are EGFR Positive Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Mesothelioma. Dr. Jackman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Janne's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile